Compare Medtronic PLC (MDT) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs AT&T Inc. — how do they compare? Medtronic PLC trades at $82.67 (market cap $106.61B), while AT&T Inc. trades at $21.96 (market cap $152.52B). The key difference: AT&T Inc. is the larger of the two by market cap, and AT&T Inc. pays the higher dividend (5.06%). Which is the better fit depends on your goals.
| MDT | T | |
|---|---|---|
Market Cap | $106.61B | $152.52B |
Sector | Health | Media |
52-Week High | $105.35 | $29.62 |
52-Week Low | $73.75 | $20.49 |
Enterprise Value | $125.36B | $297.87B |
Dividend Yield | 3.46% | 5.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
AT&T (T) trades at $21.91, up 0.52% today, with a bullish technical signal and strong fundamentals including a 17.47% net income margin and consistent earnings beats. The stock shows improving cash flow trends, with net cash flow turning positive to $15.12B in 2025. Recent news highlights fiber expansion and competitive threats from Starlink, while analyst consensus leans toward a buy with a $26.18 price target.
The outlook is cautiously optimistic given attractive valuation multiples like a P/E of 7.34 and a 19.95% ROE, but risks include intense telecom competition and debt levels. The stock offers a dividend yield supported by sustainable cash flows, positioning it as a value play with moderate growth potential amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
